TC Biopharm (Holdings) Plc (TCBP) is rising on the charts today, up 13.53% to trade at $1.76 at last check-in early trading. On Tuesday, shares in TC Biopharm (TCBP) rise 9.15% to close the day at $1.55. The volume of shares traded was 0.43 million, which is lower than the average volume over the last three months of 2.49 million. During the trading session, the stock oscillated between $1.40 and $1.61. TCBP’s stock has lost -6.63% of its value in the previous five sessions and moved 64.67% over the past one month, but has lost -26.89% on a year-to-date basis. TCBP stock is rising after a strategic success in Britain.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
What TCBP has accomplished?
TC Biopharm (TCBP) is a clinical-stage biopharmaceutical business focused on the development, marketing, and discovery of gamma-delta T cell treatments for the treatment of cancer and viral infections, including human effectiveness findings in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that have features from both the innate and adaptive immune systems, as well as the ability to distinguish between healthy and sick tissue. To efficiently detect, target, and destroy both liquid and solid tumors in cancer, TCBP adopts an allogeneic strategy in both unmodified and CAR-modified gamma delta t-cells.
TC Biopharm (TCBP) reported today that it has effectively enlisted the UK brand name “CryoTC”.
- The brand name is for TCBP’s exclusive interaction for freezing and defrosting its lead oncology item, OmnImmune.
- CryoTR is TC BioPharm’s novel course of cryopreservation, which is acted in a controlled rate cooler utilizing an improved convention.
- OmnImmune is an allogeneic unmodified cell treatment comprising actuated and extended gamma delta T cells.
- OmnImmune includes GDT cells obtained from solid contributors, initiated and extended in huge numbers prior to being refined figured out and cryopreserved for ensuing defrosting and mixture into patients.
- Being the primary gamma delta cell treatment organization with a frozen/defrosted item in the center is one more achievement accomplished by TCBP.
How this move will assist TCBP with continuing further?
This original freeze-defrost process really lays out OmnImmune as an ‘off the rack’ cell treatment, permitting TC Biopharm (TCBP) to battle assembling, boat, and store the item all over the planet for the possible therapy of AML and other blood tumors. Given the numerous advancement preliminaries and projects we are progressing with OmnImmune, TCBP is satisfied to have this brand name add to its image insurance and keep on approving its situation at the very front of development in the gamma delta vertical.